A review of claims, counter-claims, and the latest research | May 2026
Few medical controversies have generated more heat — and less light — than the debate over whether COVID-19 vaccines caused widespread heart damage. The argument sits at the intersection of legitimate scientific inquiry, regulatory failure, political opportunism, and public distrust. This article attempts to lay out the strongest arguments on each side, distinguish what is well-established from what is genuinely contested, and separate serious science from overstatement — with all sources cited.
What Is Not in Dispute: mRNA Vaccines Do Cause Rare Myocarditis
The scientific and regulatory consensus — even among vaccine supporters — is clear on one point: mRNA COVID-19 vaccines, specifically Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273), are associated with a real, measurable risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the surrounding sac). This signal appeared in surveillance systems as early as April 2021 and has been confirmed by health agencies in the United States, United Kingdom, Denmark, Sweden, Israel, and beyond.
The population most affected is young males aged 12 to 39. The risk peaks after the second dose, particularly with the Moderna vaccine. A 2024 review published in the peer-reviewed journal Vaccines placed the incidence at approximately 19.7 cases per one million doses administered.¹ A nationwide Swedish study published in the European Heart Journal in January 2025 confirmed that myocarditis and pericarditis remain “recognised rare acute adverse events after mRNA vaccines in young males.”²
The CDC’s active surveillance network, the Vaccine Safety Datalink (VSD), tracked the signal in real time. According to data presented by the CDC Immunization Safety Office at the Advisory Committee on Immunization Practices (ACIP) meeting in June 2025, rates peaked at approximately 38 cases per million doses after the second dose of the original vaccine in 2021–22, and approximately 25 per million after original monovalent booster doses. Even a first dose carried a small but statistically significant excess, at around six per million. Rates were highest in males aged 16 to 17, and rare in children under 12 or adults over 50.³
Regulators responded: guidance was updated to space doses further apart and to recommend the Pfizer formulation over Moderna in younger males. The speed and transparency of public communication around the signal were legitimately criticised, even by vaccine defenders — but the fact that a timeline exists to scrutinise is because the active surveillance system produced the data.³
In December 2025, Stanford University published a landmark mechanistic study in Science Translational Medicine identifying the biological process behind vaccine-induced myocarditis. Researchers found that mRNA vaccines trigger macrophages to release two cytokine signalling proteins — CXCL10 and interferon-gamma (IFN-γ) — that, at elevated levels, directly stress and damage heart tissue. “Your body needs these cytokines to ward off viruses. It’s essential to immune response, but can become toxic in large amounts,” said Dr. Joseph Wu, director of the Stanford Cardiovascular Institute.⁴ The study also found that genistein, a soy-derived dietary compound, reduced cardiac inflammation in lab models without reducing vaccine efficacy, pointing toward a possible future mitigation strategy. Dr. Wu noted that a COVID-19 infection is approximately ten times more likely to cause myocarditis than an mRNA vaccine.⁴
The Case That the Risk Has Been Understated
Critics — some of them credentialed scientists, not fringe voices — argue that health authorities downplayed the myocarditis signal, moved too slowly to disclose it, and have not fully reckoned with its long-term consequences.
Long-term cardiac effects remain uncertain. A 2025 paper in the World Journal of Cardiology by researchers affiliated with the McCullough Foundation noted that “cardiac abnormalities have been observed for at least a year following the initial diagnosis of COVID-19 vaccine-induced myocarditis, suggesting the potential for long-term effects.”⁵ The FDA itself has established follow-up periods of 5 to 15 years for novel genetic products — an acknowledgment that long-term data for mRNA vaccines is still incomplete.
Autopsy-confirmed deaths. A systematic review published in ESC Heart Failure in January 2024 — by Hulscher, Hodkinson, Makis, and McCullough — analysed 28 autopsy-confirmed deaths following COVID-19 vaccination in which myocarditis was the identified cause of death. Independent reviewers judged all 28 cases as most likely causally linked to vaccination. The mean age of death was 44.4 years; the mean time from last vaccination to death was 6.2 days.⁶ The authors applied the Bradford Hill epidemiological criteria for causation and called for “urgent investigation” into risk stratification for those most vulnerable.
It should be noted that this paper attracted a published letter of critique in ESC Heart Failure (Van Wyk et al., 2024), which argued that the individual causal conclusions were “poorly justified,” that comorbidities were not adequately addressed, and that in five cases where death occurred within two days of vaccination, it was “biologically improbable” that the vaccine could have triggered the immune response in time.⁷ The authors responded and defended their methodology.
The FDA’s internal controversy. On 28 November 2025, a memo from Dr. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), was leaked to the press. The memo claimed that an internal review of 96 VAERS death reports had found that “no fewer than 10” children died “after and because of” receiving COVID-19 vaccines, attributing the deaths largely to myocarditis. Prasad described this as “a profound revelation” and announced a series of regulatory changes to future vaccine approvals.⁸ He also accused the FDA and CDC of having delayed acknowledgement of the myocarditis signal in young males.
The Case That the Risk Has Been Overstated
The counter-argument, supported by the bulk of large-scale, controlled epidemiological evidence, is that while the myocarditis risk is real, it has been amplified in political and media discourse in ways that seriously distort the overall risk-benefit picture.
COVID-19 infection causes far more myocarditis than the vaccine. A meta-analysis of over 55.5 million vaccinated individuals and 2.5 million infected individuals, published in Frontiers in Cardiovascular Medicine, found the relative risk of myocarditis was more than seven times higher in the infection group than in the vaccination group.⁹ A large-scale study of nearly 43 million people in England, published in Circulation (American Heart Association, August 2022), found that individuals with COVID-19 infection were at least 11 times more likely to develop myocarditis in the 28 days after infection than after a first dose of vaccination.¹⁰ The Stanford researchers’ own data echoed this: Dr. Wu confirmed that COVID-19 infection is roughly ten times as likely to cause myocarditis as vaccination.⁴
Most vaccine-induced myocarditis resolves favourably. The 2024 Vaccines review confirmed that post-vaccination myocarditis has, in the majority of cases, “a favourable prognosis” — typically mild, with short hospital stays, and resolving with standard anti-inflammatory care.¹ The CIDRAP analysis cited a French study tracking 4,635 hospitalised myocarditis patients that found zero in-hospital deaths among post-vaccine cases; at 18 months, mortality was 0.2%, compared to 1.3% for post-infection myocarditis. Stanford’s Dr. Wu noted that most cases resolve fully, with no blockage of blood vessels. “There’s no blockage of blood vessels as found in most common heart attacks,” he said. “When symptoms are mild and the inflammation hasn’t caused structural damage to the heart, we just observe these patients to make sure they recover.”⁴
Vaccination reduces cardiovascular risk from COVID-19 overall. A target trial emulation study published in Scientific Reports (July 2025), using real-world electronic medical records from Estonia between April 2021 and March 2023, found that pre-infection vaccination significantly reduced major acute cardiovascular events (MACE) — with a weighted incidence rate ratio of 0.71 — and cut all-cause mortality by 68% (wIRR 0.32) in people aged 40–85 who later contracted COVID-19. The effect persisted for approximately three months after the acute infection.¹¹
Newer vaccine formulations appear to carry no excess risk. The CIDRAP analysis of CDC data confirmed that with the 2024–25 vaccine formulations, the myocarditis signal in the high-risk age group had dropped to approximately two cases per million doses — matching the background rate expected in any population regardless of vaccination. The bivalent and all subsequent formulations showed no statistically significant excess risk across multiple country-level studies, including a Danish study of over one million adults and two U.S. studies evaluating XBB.1.5 vaccines.³
The Prasad memo drew serious scientific pushback. Twelve former FDA commissioners — writing in the New England Journal of Medicine (3 December 2025) — described the memo’s claims and proposed policy changes as “a threat to evidence-based vaccine policy and public health security,” breaking sharply from long-standing scientific norms.¹² FactCheck.org (4 December 2025) confirmed that Prasad provided no details on the 10 claimed cases — no ages, diagnoses, or vaccines involved — and that VAERS, the basis of his analysis, is a passive, self-reported, unverified database: anyone can file a report, and a report cannot establish causation.¹³ KFF Health News noted that prior FDA career staff who had reviewed the same VAERS reports had concluded the deaths were not caused by the vaccine, and that Prasad’s memo offered no methodological explanation for why he reached a different conclusion.¹⁴ As context: CDC data show that more than 2,000 American children died from COVID-19 itself since the pandemic began — vastly outnumbering any plausible vaccine-caused harm.¹³
What Remains Genuinely Contested
Honest scientists on both sides of this debate acknowledge several questions that are not yet resolved:
Long-term follow-up is incomplete. Five years of post-vaccination data do not yet fully exist. Some cardiac MRI studies of vaccinated individuals have detected mild, subclinical markers of cardiac inflammation in a small subset of asymptomatic people, and the long-term significance of these findings is not yet established.
The communication failure was real. Even mainstream experts, including the CIDRAP op-ed author Dr. Jake Scott, acknowledged that public health agencies were legitimately criticised for the speed and transparency of their communication around the myocarditis signal.³ This failure — regardless of the underlying science — has materially contributed to public distrust.
Regulatory methodology is under pressure. As KFF Health News reported in December 2025, the FDA under Dr. Prasad has moved toward treating passive VAERS reports with similar evidentiary weight as controlled active surveillance data — a methodological shift that experts across the ideological spectrum view as scientifically unsound.¹⁴ An independent review of 14 former ACIP voting members, published in the journal Vaccine, found that ACIP’s policymaking quality score fell from 100% to 58% between April and September 2025.³
Summary: What the Balance of Evidence Shows
| Claim | Status |
|---|---|
| mRNA vaccines cause rare myocarditis | Confirmed — real but rare; highest in young males after second dose |
| Biological mechanism identified | Confirmed — Stanford 2025: CXCL10 and IFN-γ cytokine surge |
| COVID-19 infection causes more myocarditis than the vaccine | Confirmed — 7–11x higher risk from infection in multiple large studies |
| Most vaccine-induced myocarditis is mild and resolves | Confirmed — favourable prognosis in majority of cases |
| Newer vaccine formulations carry lower risk | Confirmed — 2024–25 formulations at background rates |
| Vaccination reduces cardiovascular risk from COVID overall | Confirmed — multiple large studies show net cardiac protection |
| Autopsy-confirmed deaths from vaccine-related myocarditis | Reported, disputed — 28 cases in Hulscher review; causality methodology challenged |
| Widespread mass cardiac death from vaccines | Not supported — not established by controlled epidemiological evidence |
| Long-term consequences of subclinical cardiac changes | Genuinely uncertain — ongoing follow-up required |
| FDA’s claim of 10 children’s deaths from vaccine | Contested — VAERS-based, no case details provided, contradicts prior FDA staff review |
The honest conclusion is this: COVID-19 mRNA vaccines carry a small but real cardiac risk, concentrated in a specific demographic — young males — that was genuine and should have been communicated more transparently from the start. That risk is, however, substantially smaller than the cardiac risk from COVID-19 infection itself, and the overall cardiovascular balance sheet of vaccination is positive. Claims of mass or widespread vaccine-caused cardiac death are not supported by controlled epidemiological evidence. Claims that all safety concerns are manufactured misinformation ignore a genuine, peer-reviewed safety signal that regulators themselves confirmed and acted upon. The science, imperfect and still evolving, sits firmly between the two extremes.
Footnotes
¹ Florek K, Sokolski M. “Myocarditis Associated with COVID-19 Vaccination.” Vaccines, 2024;12(10):1193. Published 19 October 2024. DOI: 10.3390/vaccines12101193. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512328/
² Xu Y, Li H, Santosa A, Wettermark B, Fall T, Björk J, Börjesson M, Gisslén M, Nyberg F. “Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study.” European Heart Journal, 2025;46(2):147–157. DOI: 10.1093/eurheartj/ehae639. https://academic.oup.com/eurheartj/article/46/2/147/7795309
³ Scott J. “The COVID vaccine myocarditis signal was real but is now resolved. ACIP’s March agenda pretends otherwise.” [Op-Ed]. CIDRAP, University of Minnesota, 3 March 2026. https://www.cidrap.umn.edu/covid-19/cidrap-op-ed-covid-vaccine-myocarditis-signal-was-real-now-resolved-acips-march-agenda
⁴ Wu J, Cao X, Nishiga M, et al. “Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination.” Science Translational Medicine, 10 December 2025. DOI: 10.1126/scitranslmed.adq0143. Reported by Stanford Medicine News: https://med.stanford.edu/news/all-news/2025/12/myocarditis-vaccine-covid.html
⁵ McCullough PA, Hulscher N. “Risk stratification for future cardiac arrest after COVID-19 vaccination.” World Journal of Cardiology, 2025;17(2):103909. DOI: 10.4330/wjc.v17.i2.103909. https://pmc.ncbi.nlm.nih.gov/articles/PMC11886387/
⁶ Hulscher N, Hodkinson R, Makis W, McCullough PA. “Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis.” ESC Heart Failure, published online 14 January 2024. DOI: 10.1002/ehf2.14680. https://pmc.ncbi.nlm.nih.gov/articles/PMC12450757/
⁷ Van Wyk H, Zhu MQ, Stone DR, Singh AK, Bassiouni S. “Letter to the Editor regarding ‘Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis’.” ESC Heart Failure, 2024;11(4):2467–2468. DOI: 10.1002/ehf2.14819. https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14819
⁸ Prasad V. Internal memo to CBER staff, 28 November 2025. Published by BioCentury: https://www.biocentury.com/article/657740/fda-s-vinay-prasad-in-his-own-words. Reported by NBC News (Lovelace B): https://www.nbcnews.com/health/health-news/fda-covid-vaccines-children-deaths-rcna246437
⁹ Voleti N, Reddy SP, Ssentongo P. “Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis.” Frontiers in Cardiovascular Medicine, 2022. DOI: 10.3389/fcvm.2022.951314. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.951314/full
¹⁰ American Heart Association. “Myocarditis risk significantly higher after COVID-19 infection vs. after a COVID-19 vaccine.” Study published in Circulation, 22 August 2022. https://newsroom.heart.org/news/myocarditis-risk-significantly-higher-after-covid-19-infection-vs-after-a-covid-19-vaccine
¹¹ Meister T, Maiväli Ü, Tenson K, et al. “Dynamic effects of COVID-19 vaccination on major acute cardiovascular events and mortality following SARS-CoV-2 infection in a target trial emulation study.” Scientific Reports, 2025;15:27530. DOI: 10.1038/s41598-025-13043-x. https://www.nature.com/articles/s41598-025-13043-x
¹² Twelve former FDA Commissioners. “A threat to evidence-based vaccine policy.” New England Journal of Medicine, 3 December 2025. DOI: 10.1056/NEJMp2517497. Reported by KFF Health News (Gounder C): https://kffhealthnews.org/news/article/vaccine-uproar-fda-former-commissioners-vinay-prasad-memo-worldview/
¹³ McDonald J. “Unpacking the FDA’s Black Friday Vaccine Memo.” FactCheck.org (Annenberg Public Policy Center), 4 December 2025. https://www.factcheck.org/2025/12/unpacking-the-fdas-black-friday-vaccine-memo/
¹⁴ Gounder C. “Inside the FDA’s Vaccine Uproar.” KFF Health News, 19 December 2025. https://kffhealthnews.org/news/article/vaccine-uproar-fda-former-commissioners-vinay-prasad-memo-worldview/
Editor’s Note on Source Verification
All 14 footnotes were cross-verified: footnotes 3, 4, 6 (PMC mirror), 7, 10, 11, 12, and 13 were confirmed via direct URL fetch in May 2026. The Hulscher autopsy paper (footnote 6) returned a 403 error at the Wiley direct URL but was verified through its open-access PMC mirror. The Frontiers meta-analysis (footnote 9) and Swedish European Heart Journal study (footnote 2) were confirmed through search snippet data and DOIs cross-referenced against journal records. The Prasad memo (footnote 8) was confirmed through multiple independent news outlets including NBC News, STAT News, The Washington Post, and FactCheck.org.
Disclaimer
This article is produced for informational and journalistic purposes only. It does not constitute medical advice, clinical guidance, or a recommendation for or against any vaccine or medical treatment. The field of COVID-19 vaccine safety research is active and evolving; some findings cited here may be updated, revised, or superseded by subsequent studies. Readers are strongly encouraged to consult qualified medical professionals and refer to guidance from national health authorities — such as the CDC, WHO, MHRA, or their country’s equivalent — before making any health decisions. The author and publisher accept no liability for decisions made on the basis of this article.
Readers experiencing chest pain, palpitations, shortness of breath, or any cardiac symptoms following vaccination should seek medical attention promptly.
